Naegelen C, Isola H, Dernis D, Maurel J-P, Tardivel R, Bois S, Vignoli C, Cazenave J-P
EFS Bourgogne-Franche-Comté, 25000 Besançon, France.
Transfus Clin Biol. 2009 May;16(2):179-89. doi: 10.1016/j.tracli.2009.03.022. Epub 2009 May 13.
The techniques for inactivation of pathogens in labile blood products (LBP) would appear to be the new strategy which will permit us to increase transfusion safety in the face of the risks of transmission of pathogenic agents by LBP. Various methods are in the course of development or already validated and used in France. The latter only apply however to plasma or platelet concentrates. The mechanisms of action and the efficacy of inactivation and attenuation of pathogenic agents vary with the different techniques. Each of these constitutes a preparative procedure composed of unit steps which have to be fully mastered in order to ensure the quality and transfusion efficacy of the treated product.
使不稳定血液制品(LBP)中的病原体失活的技术似乎是一种新策略,它将使我们能够在面对LBP传播病原体风险的情况下提高输血安全性。各种方法正在研发中,或已在法国得到验证并使用。然而,后者仅适用于血浆或血小板浓缩物。病原体失活和减毒的作用机制及效果因不同技术而异。这些技术中的每一种都构成一个由单元步骤组成的制备程序,为确保处理后产品的质量和输血效果,必须全面掌握这些步骤。